Technologies

Invention Summary

U-6096 allows for the detection of Myalgic Encephalomyelitis, more commonly known as Chronic Fatigue Syndrome (CFS). At present, there are no accurate means of distinguishing this disorder from various conditions such as depression, which can make diagnosis and treatment difficult. Through the use of genetic testing, this methodology can differentiate CFS from other diseases improving patient outcomes, increasing the efficacy of physicians, and allowing for improvements in research.

Market Opportunity

Relevant Statistics:

• Approximately 750,000 individuals in the United States have CFS
• The current cost for medications to ameliorate symptoms is $8,675 per person, per year
• Diagnostic tests have a wide range of costs ranging from tens of dollars to many thousands. However, modern exhaustive genetic tests often cost between $500 and $1000

The possible market can be derived in one of two ways, either by evaluating the current amount individuals are spending on treatments or by examining the market based on similar diagnostic tests.

Market from current patient costs. $ 6.53 BN Cases * current drug expenses

Diagnostic Market $ 750 MN Cases * Cost of modern diagnostic costs

Initial Target Market $ 75 MN One tenth of the Diagnostic Market